var data={"title":"Human papillomavirus quadrivalent vaccine: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Human papillomavirus quadrivalent vaccine: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/228154?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=human-papillomavirus-quadrivalent-vaccine-drug-information\" class=\"drug drug_general\">see &quot;Human papillomavirus quadrivalent vaccine: Drug information&quot;</a> and <a href=\"topic.htm?path=human-papillomavirus-quadrivalent-vaccine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Human papillomavirus quadrivalent vaccine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5994263\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Gardasil</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3270170\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Vaccine</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Vaccine, Inactivated Virus</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3270179\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=human-papillomavirus-quadrivalent-vaccine-drug-information\" class=\"drug drug_general\">see &quot;Human papillomavirus quadrivalent vaccine: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note: </b>Consult CDC/ACIP annual immunization schedules for additional information including specific detailed recommendations for catch-up scenarios and/or care of patients with high-risk conditions. According to ACIP, doses administered &le;4 days before minimum interval or age are considered valid; however, local or state mandates may supersede this timeframe (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Primary immunization: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CDC (ACIP) recommended immunization schedule: In a 2-dose series, minimum interval between the first and second dose is 5 months. In a 3-dose schedule, minimum interval between first and second doses is 4 weeks; the minimum interval between the second and third dose is 12 weeks; the minimum interval between first and third doses is 5 months (CDC/ACIP [Meites 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Non-immunocompromised patients and certain medical conditions: Asplenia, asthma, chronic granulomatous disease, chronic liver disease, chronic lung disease, chronic renal disease, central nervous system, anatomic barrier defects (eg, cochlear implant), complement deficiency, diabetes, heart disease, or sickle cell disease:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Children &ge;9 years and Adolescents &lt;15 years: <i>2-dose series</i>: IM: 0.5 mL at 0, and 6 to 12 months. Administer first dose at age 11 to 12 years; patients with any history of sexual abuse or assault, vaccination should be started at 9 years of age.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Adolescents &ge;15 years: <i>3-dose series</i>: IM: 0.5 mL at 0, 1 to 2, and 6 months</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Immunocompromised patients, including those with immunocompromising conditions that might reduce cell-mediated or humoral immunity, such as B lymphocyte antibody deficiencies, T lymphocyte complete or partial defects, HIV infection, malignant neoplasms, transplantation, autoimmune disease, or immunosuppressive therapy: Children &ge;9 years and Adolescents: <i>3-dose series</i>: IM: 0.5 mL at 0, 1 to 2, and 6 months</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Catch-up immunization:</b> CDC/ACIP recommendations (Meites 2016): <b>Note:</b> Do not restart the series. If doses have been given, begin the below schedule at the applicable dose number. Children &ge;9 years and Adolescents: IM: 0.5 mL per dose for a total of 2 to 3 doses (See CDC/ACIP recommendations above for 2-dose vs. 3-dose schedule criteria):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">First dose given on the elected date</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Second dose given at least 4 weeks after the first dose (for a 3-dose schedule) or 5 months after the first dose (for a 2-dose schedule).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Third dose (for a 3-dose schedule) given at least 12 weeks after the second dose and at least 5 months after the first dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Immunization:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CDC (ACIP) recommended immunization schedule: Vaccination recommended in females and transgender persons &le;26 years or males &le;21 years if not previously vaccinated or have not completed the series (typically administer first dose at age 11 to 12 years). Vaccination for males 22 through 26 years of age is recommended if immunocompromised (including HIV) and for men who have sex with men and may be considered for any other male in this age group. Second and third doses may be given after age 26 years to complete a previously initiated series (CDC/ACIP [Meites 2016]). Adults &le;26 years:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Have not received any doses:</i> 3-dose series: IM: 0.5 mL at 0, 1 to 2, and 6 months. There should be a 4-week minimum interval between the first and second dose; a 12-week minimum interval between the second and third dose; a 5-month minimum interval between the first and third dose.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Partially vaccinated, first dose before 15 years of age</i>:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">If 2 doses administered at least 5 months apart: No additional doses needed</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">If only a single dose or if doses &lt;5 months apart: IM: Administer one additional 0.5 mL dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Partially vaccinated, first dose at 15 years of age or later</i>: Complete 3-dose series: IM: There should be a 4-week minimum interval between the first and second dose; a 12-week minimum interval between the second and third dose; a 5-month minimum interval between the first and third dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Manufacturer's labeling: Adults &le;26 years: IM: 0.5 mL per dose for a total of 3 doses; administer the second and third doses at 2 and 6 months after initial dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3000504\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3270180\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IM: Shake suspension well prior to use; do not use suspension if it is discolored or contains particulate matter; do not dilute or mix with other vaccines. Administer IM into the deltoid region of the upper arm or in the higher anterolateral area of the thigh; <b>not for IV, intradermal, or SubQ administration</b><b>.</b> Do not mix with other vaccines or injections; separate needles and syringes should be used for each injection (ACIP [Kroger 2017]). To prevent syncope related injuries, adolescents and adults should be vaccinated while seated or lying down (ACIP [Kroger 2017]). US law requires that the date of administration, the vaccine manufacturer, lot number of vaccine, and the administering person&rsquo;s name, title, and address be entered into the patient&rsquo;s permanent medical record.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">For patients at risk of hemorrhage following intramuscular injection, the vaccine should be administered intramuscularly if, in the opinion of the physician familiar with the patient's bleeding risk, the vaccine can be administered by this route with reasonable safety. If the patient receives antihemophilia or other similar therapy, intramuscular vaccination can be scheduled shortly after such therapy is administered. A fine needle (23 gauge or smaller) can be used for the vaccination and firm pressure applied to the site (without rubbing) for at least 2 minutes. The patient should be instructed concerning the risk of hematoma from the injection. Patients on anticoagulant therapy should be considered to have the same bleeding risks and treated as those with clotting factor disorders (ACIP [Kroger 2017]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3000564\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Store refrigerated at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F). Do not freeze. Protect from light. Administer as soon as possible after removing it from refrigeration; can be out of refrigeration (at temperatures at or below 25&deg;C [77&deg;F]) for a total time of not more than 72 hours.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3270171\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prevention of cervical, vulvar, vaginal, and anal cancer caused by HPV types 16 and 18; genital warts caused by HPV types 6 and 11; cervical adenocarcinoma in situ; and vulvar, vaginal, cervical, or anal intraepithelial neoplasia caused by HPV types 6, 11, 16, 18 (FDA approved in females ages 9 to 26 years)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Prevention of genital warts caused by HPV types 6 and 11; anal cancer caused by HPV types 16 and 18; and anal intraepithelial neoplasia caused by HPV types 6, 11, 16, and 18 (FDA approved in males ages 9 to 26 years)</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The Advisory Committee on Immunization Practices (ACIP) recommends routine vaccination for females and males 11 to 12 years of age; for patients with any history of sexual abuse or assault, vaccination should be started at 9 years of age. Catch-up vaccination is recommended for females and transgender persons 13 to 26 years of age and males 13 to 21 years of age. Vaccination for males 22 through 26 years of age is recommended if immunocompromised (including HIV) and for men who have sex with men and may be considered for any other male in this age group (CDC/ACIP [Meites 2016]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9518288\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Papillomavirus vaccine types 6, 11, 16, 18 (Gardasil) may be confused with Papillomavirus vaccine types 16, 18 (Cervarix)</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Papillomavirus vaccine types 6, 11, 16, 18 (Gardasil) may be confused with Papillomavirus vaccine 9-valent (Gardasil 9)</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">HPV (human papilloma virus vaccine) may be confused with IPV (inactivated poliovirus vaccine)</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">HPV (human papilloma virus vaccine) may be confused with HBV (previously used for hepatitis B vaccine; HepB is correct abbreviation)</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">HPV (human papilloma virus vaccine) may be confused with Hib (<i>Haemophilus</i> b conjugate vaccine)</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">HPV4 (human papillomavirus vaccine [quadrivalent]) may be confused with HepA (hepatitis A vaccine)</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">HPV4 (human papillomavirus vaccine [quadrivalent]) may be confused with HepB (hepatitis B vaccine)</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3000558\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Dizziness, headache</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Injection site pruritus (females)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Diarrhea (males), nausea, toothache (females), vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Erythema at injection site, hematoma at injection site (females), pain at injection site (more common in females), swelling at injection site (more common in females)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia, limb pain (females), myalgia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Oropharyngeal pain (males), upper respiratory tract infection (males)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Acute disseminated encephalomyelitis, anaphylactoid reaction, anaphylaxis, arthropathy (impaired joint movement at injection site), asthma, autoimmune disease, autoimmune hemolytic anemia, bronchospasm, cellulitis, chills, fatigue, Guillain-Barr&eacute; syndrome, hypersensitivity reaction, immune thrombocytopenia, lymphadenopathy, malaise, neuromuscular disease, pancreatitis, paralysis, pulmonary embolism, syncope (may result in falls or be associated with tonic-clonic movements), transverse myelitis, urticaria, weakness seizure, sepsis, syncope (may result in falls with injury or be associated with tonic-clonic movements), transverse myelitis, urticaria, weakness</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3000514\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to any component of the vaccine or to a previous dose of the vaccine</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3000553\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1 mg/mL) for anaphylactoid and/or hypersensitivity reactions should be available during vaccine use (NACI 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Syncope: Syncope has been reported with use of injectable vaccines and may result in serious secondary injury (eg, skull fracture, cerebral hemorrhage); typically reported in adolescents and young adults and within 15 minutes after vaccination. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs (ACIP [Kroger 2017]; NACI 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Acute illness: The decision to administer or delay vaccination because of current or recent febrile illness depends on the severity of symptoms and the etiology of the disease. Defer administration in patients with moderate or severe acute illness (with or without fever); vaccination should not be delayed for patients with mild acute illness (with or without fever) (NACI 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bleeding disorders: Use with caution in patients with a history of bleeding disorders (including thrombocytopenia); bleeding/hematoma may occur from IM administration; if the patient receives antihemophilia or other similar therapy, IM injection can be scheduled shortly after such therapy is administered (ACIP [Kroger 2017]; NACI 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Human papillomavirus (HPV) infection: There is no evidence that individuals already infected with HPV will be protected; those already infected with 1 or more HPV types were protected from disease in the remaining HPV types. Not for the treatment of active disease; will not protect against diseases not caused by HPV vaccine types 6, 11, 16, and 18.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anticoagulant therapy: Use with caution in patients receiving anticoagulant therapy; bleeding/hematoma may occur from IM administration (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vaccines: In order to maximize vaccination rates, simultaneous administration (ie, &gt;1 vaccine on the same day at different anatomic sites) is recommended of all age-appropriate vaccines (live or inactivated) for which a person is eligible at a single clinic visit, unless contraindications exist. The NACI prefers each dose in a HPV vaccine series be the same vaccine when possible; however, if the previous vaccine is not known then any of the HPV vaccines licensed for use in Canada may be used. (<b>Note:</b> The HPV2 vaccine only protects again HPV types 16 and 18 and is not approved for use in males.) (NACI 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Altered immunocompetence: May be administered to those who are immunosuppressed. Consider deferring immunization during periods of severe immunosuppression (eg, patients receiving chemo/radiation therapy or other immunosuppressive therapy [including high dose corticosteroids]); may have a reduced response to vaccination (NACI 2017). In general, household and close contacts of persons with altered immunocompetence may receive all age-appropriate vaccines. Inactivated vaccines should be administered &ge;2 weeks prior to planned immunosuppression when feasible; inactivated vaccines administered during chemotherapy should be readministered after immune competence is regained (ACIP [Kroger 2017]; IDSA [Rubin 2014]; NACI 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Yeast: Product may contain yeast.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Effective immunity: Vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval. Vaccines may not be effective if administered during periods of altered immune competence (NACI 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Maximum efficacy: The entire 3-dose regimen should be completed for maximum efficacy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299822\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3000561\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12994&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Belimumab: May diminish the therapeutic effect of Vaccines (Inactivated). Management: Patients should receive inactivated vaccines prior to initiation of belimumab therapy whenever possible, due to the risk for an impaired response to the vaccine during belimumab therapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: May diminish the therapeutic effect of Vaccines (Inactivated). Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting fingolimod. If vaccinated during fingolimod therapy, revaccinate 2 to 3 months after fingolimod discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immunosuppressants: May diminish the therapeutic effect of Vaccines (Inactivated). Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<b> Exceptions: </b>Cytarabine (Liposomal).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Venetoclax: May diminish the therapeutic effect of Vaccines (Inactivated).<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3000510\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Administration of the human papillomavirus vaccine during pregnancy is not recommended. Although exposure to human papillomavirus vaccine has not been causally associated with adverse pregnancy outcomes, until additional information is available the vaccine series (or completion of the series) should be delayed until pregnancy is completed (NACI 2017).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The manufacturer recommend pregnancy be avoided during the vaccination series.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Exposures to quadrivalent human papillomavirus vaccine during pregnancy should be reported to the manufacturer (800-267-2594) or Vaccine Safety Section at Public Health Agency of Canada (866-844-0018 or http://www.phac-aspc.gc.ca/im/vssv/index-eng.php).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5177947\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Screening for HPV is not required prior to vaccination. Observe for syncope for 15 minutes following administration (ACIP [Kroger 2017]). If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to reestablish adequate cerebral perfusion.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Females: Gynecologic screening exam, papillomavirus test; screening for cervical cancer should continue per current guidelines following vaccination</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3001513\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Contains inactive human papillomavirus (HPV) proteins HPV 6 L1, HPV 11 L1, HPV 16 L1, and HPV 18 L1 which produce neutralizing antibodies to prevent cervical cancer, cervical adenocarcinoma, cervical, vaginal and vulvar neoplasia, and genital warts caused by HPV. The vaccine has not been shown to provide cross-protective efficacy to HPV types not contained in the vaccine. Immunogenicity has been measured by the percentage of persons who became seropositive for antibodies contained in the vaccine; the minimum anti-HPV antibody concentration needed to protect against disease has not been determined. The population benefit to vaccination is influenced by the prevalence of HPV within the geographic area and subject characteristics (eg, lifetime sexual partners).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Efficacy: In females 16 to 26 years of age, HPV4 has shown to be ~100% effective against HPV types 16- and 18-related cervical disease and 95% to 99% effective against external genital lesions related to HPV types 6, 11, 16, or 18. In males 16 to 26 years of age, HPV4 vaccine has shown to be 84% to 100% effective against external genital lesions related to HPV types 6, 11, 16, or 18. In females 24 to 45 years of age, the vaccine was shown to be 91% effective against HPV 6, 11, 16, and 18 persistent infection and cervical or external genital disease and 83% effective against HPV types 16 and 18 only. In addition, vaccination against HPV types 16 and 18 may prevent ~70% of anogenital cancers and 60% of high-risk precancerous cervical lesions (NACI 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9559927\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset: Seroconversion was observed 1 month following the last dose of vaccine</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: Duration unknown. Clinical studies followed HPV4 vaccinated participants for 10 years and found no evidence of waning protection (NACI 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10278556\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">Comparison of HPV vaccines: Cervarix and Gardasil are both vaccines formulated to protect against infection with the human papillomavirus. Both are inactive vaccines which contain proteins HPV16 L1 and HPV 18 L1, the cause of &gt;70% of invasive cervical cancer. The vaccines differ in that Gardasil also contains HPV 6 L1 and HPV 11 L1 proteins which protect against 75% to 90% of genital warts. The vaccines also differ in their preparation and adjuvants used. The viral proteins in Cervarix are prepared using <i>Trichoplusia ni</i> (insect cells) which are adsorbed onto an aluminum salt which is also combined with a monophosphoryl lipid. The viral proteins in Gardasil are prepared using <i>S. cerevisiae</i> (baker's yeast) which are then adsorbed onto an aluminum salt. Results from a short-term study (measurements obtained 1 month following the third vaccination in the series) have shown that the immune response to HPV 16 and HPV 18 may be greater with Cervarix; although the clinical significance of this difference is not known, local adverse events may also occur more frequently with this preparation. Both vaccines were effective and results from long-term studies are pending (Einstein 2009).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038887\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Gardasil (AE, AR, AT, AU, BE, BG, BH, CH, CL, CO, CR, CZ, DE, DK, EC, EE, ES, FI, FR, GB, GR, GT, HK, HN, HR, HU, ID, IE, IL, IS, IT, JP, KR, KW, LB, LT, LU, MT, MY, NI, NL, NO, NZ, PA, PE, PH, PL, PT, QA, RO, RU, SA, SE, SG, SK, SV, TH, TR, TW, UA, UY, VN, ZW)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/human-papillomavirus-quadrivalent-vaccine-pediatric-drug-information/abstract-text/3960626/pubmed\" target=\"_blank\" id=\"3960626\">3960626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Block SL, Nolan T, Sattler C, et al, &ldquo;Comparison of the Immunogenicity and Reactogenicity of a Prophylactic Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine in Male and Female Adolescents and Young Adult Women,&rdquo; <i>Pediatrics</i>, 2006, 118(5):2135-45.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/human-papillomavirus-quadrivalent-vaccine-pediatric-drug-information/abstract-text/17079588/pubmed\" target=\"_blank\" id=\"17079588\">17079588</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199 <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/human-papillomavirus-quadrivalent-vaccine-pediatric-drug-information/abstract-text/6423951/pubmed\" target=\"_blank\" id=\"6423951\">6423951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Einstein MH, Baron M, Levin MJ, et al. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. <i>Hum Vaccin</i>. 2009;5(10):507-519.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/human-papillomavirus-quadrivalent-vaccine-pediatric-drug-information/abstract-text/19684472/pubmed\" target=\"_blank\" id=\"19684472\">19684472</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gardasil (human papillomavirus quadrivalent [types 6, 11, 16, and 18] vaccine, recombinant) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co., Inc; April 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47:313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/human-papillomavirus-quadrivalent-vaccine-pediatric-drug-information/abstract-text/12534540/pubmed\" target=\"_blank\" id=\"12534540\">12534540</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kim DK, Riley LE, Harriman KH, Hunter P, Bridges CB. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older - United States, 2017. <i>MMWR Morb Mortal Wkly Rep</i>. 2017;66(5):136-138.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/human-papillomavirus-quadrivalent-vaccine-pediatric-drug-information/abstract-text/28182599/pubmed\" target=\"_blank\" id=\"28182599\">28182599</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kroger AT, Duchin J, Vazquez M. General best practice guidelines for immunization. Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP). Available at <a href=\"https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf\" target=\"_blank\">https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf</a>. Accessed April 4, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43:172.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/human-papillomavirus-quadrivalent-vaccine-pediatric-drug-information/abstract-text/10985636/pubmed\" target=\"_blank\" id=\"10985636\">10985636</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Markowitz LE, Dunne EF, Saraiya M, et.al; Centers for Disease Control and Prevention (CDC). Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). <i>MMWR Recomm Rep</i>. 2014;63(RR-05):1-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/human-papillomavirus-quadrivalent-vaccine-pediatric-drug-information/abstract-text/25167164/pubmed\" target=\"_blank\" id=\"25167164\">25167164</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Meites E, Kempe A, Markowitz LE. Use of a 2-dose schedule for human papillomavirus vaccination - updated recommendations of the Advisory Committee on Immunization Practices. <i>MMWR Morb Mortal Wkly Rep</i>. 2016;65(49):1405-1408.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/human-papillomavirus-quadrivalent-vaccine-pediatric-drug-information/abstract-text/27977643/pubmed\" target=\"_blank\" id=\"27977643\">27977643</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Petrosky E, Bocchini JA, Hariri S, et.al. Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the Advisory Committee on Immunization Practices. <i>MMWR Morb Mortal Wkly Rep</i>. 2015;64(11):300-304.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/human-papillomavirus-quadrivalent-vaccine-pediatric-drug-information/abstract-text/25811679/pubmed\" target=\"_blank\" id=\"25811679\">25811679</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reisinger KS, Block SL, Collins-Ogle M, et al, &quot;Safety, Tolerability, and Immunogenicity of Gardasil Given Concomitantly With Menactra and Adacel,&quot; <i>Pediatrics</i>, 2010, 125(6):1142-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/human-papillomavirus-quadrivalent-vaccine-pediatric-drug-information/abstract-text/20439595/pubmed\" target=\"_blank\" id=\"20439595\">20439595</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Robinson CL, Romero JR, Kempe A, et al. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger - United States, 2017. <i>MMWR Morb Mortal Wkly Rep</i>. 2017;66(5):134-135.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/human-papillomavirus-quadrivalent-vaccine-pediatric-drug-information/abstract-text/28182607/pubmed\" target=\"_blank\" id=\"28182607\">28182607</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. <i>Clin Infect Dis</i>. 2014;58(3):e44-e100.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/human-papillomavirus-quadrivalent-vaccine-pediatric-drug-information/abstract-text/24311479/pubmed\" target=\"_blank\" id=\"24311479\">24311479</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/human-papillomavirus-quadrivalent-vaccine-pediatric-drug-information/abstract-text/7746084/pubmed\" target=\"_blank\" id=\"7746084\">7746084</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12994 Version 102.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F5994263\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F3270170\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F3270179\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F3000504\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F3270180\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F3000564\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F3270171\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F9518288\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F3000558\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F3000514\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F3000553\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299822\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F3000561\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F3000510\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F5177947\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F3001513\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F9559927\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F10278556\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038887\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12994|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=human-papillomavirus-quadrivalent-vaccine-drug-information\" class=\"drug drug_general\">Human papillomavirus quadrivalent vaccine: Drug information</a></li><li><a href=\"topic.htm?path=human-papillomavirus-quadrivalent-vaccine-patient-drug-information\" class=\"drug drug_patient\">Human papillomavirus quadrivalent vaccine: Patient drug information</a></li></ul></div></div>","javascript":null}